High intensity focused ultrasound (HIFU) for prostate cancer: current clinical status, outcomes and future perspectives.
Two devices are currently available for the treatment of prostate cancer with HIFU: Sonablate® and Ablatherm®. The outcomes achieved for primary-care patient are very promissing with mid- and long-term progression-free survival rates around 70%, negative postoperative prostate biopsies almost 85%, and an excellent morbidity profile. Moreover, HIFU has a considerable potential for local recurrence after radiation failure. Recently, some early experiences on focal therapy suggest that HIFU could be an excellent option for highly selected patient.
Crouzet
Sebastien
S
Urology and Transplantation Department, Edouard Herriot Hospital, Lyon, France. sebastien.crouzet@chu-lyon.fr
Murat
Francois J
FJ
Pasticier
Gilles
G
Cassier
Philippe
P
Chapelon
Jean Y
JY
Gelet
Albert
A
D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D018579:Patient Selection; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy; D016879:Salvage Therapy; D016896:Treatment Outcome; D014463:Ultrasonography; D036761:Ultrasound, High-Intensity Focused, Transrectal / Q000295:instrumentation / Q000706:statistics & numerical data / Q000639:trends